Enhertu
Payments companies reported to CMS as associated with Enhertu. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Enhertu, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Enhertu
These are the largest totals companies reported as associated with Enhertu. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jonathan Chung | San Diego, CA | Diagnostic Radiology | $339,874.92 |
| Maria Theodoulou | Albany, NY | Medical Oncology | $328,458.12 |
| Charles Powell | New York, NY | Pulmonary Disease | $268,522.50 |
| Amy Krie | Minneapolis, MN | Medical Oncology | $263,623.57 |
| Janice Dutcher | New York, NY | $260,625.00 | |
| John Park | San Francisco, CA | Medical Oncology | $245,529.23 |
| Anne Odea | Westwood, KS | Medical Oncology | $216,011.23 |
| Wassim Mchayleh | Altamonte Springs, FL | Hematology & Oncology | $196,452.20 |
| Francis Arena | Lake Success, NY | Hematology & Oncology | $186,232.73 |
| Stephen Dyar | Greenville, SC | Hematology & Oncology | $177,682.67 |
Prescribed Enhertu?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.